Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

被引：42
|
作者：
Mehta, Anurag [1 ]
Gupta, Arjun [1 ]
Hannallah, Franck [1 ]
Koshy, Thomas [2 ]
Reimold, Sharon [2 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Cardiol, Dallas, TX 75390 USA
来源：
MELANOMA RESEARCH | 2016年 / 26卷 / 03期
关键词：
D O I：
10.1097/CMR.0000000000000251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 320
页数：2
相关论文
共 50 条
  • [41] Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
    Kielkowski, Brooke
    Mansour, Diana
    Ebbert, Brooke
    Seago, Kelsea
    Wen, Sijin
    Li, Hang
    Barrett, Christine
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [42] The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE
    Kizawa, R.
    Kuno, M.
    Washino, S.
    Shirotake, S.
    Izumi, K.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Hyodo, Y.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    Miura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1488
  • [43] Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab
    Mian, Idrees
    Yang, Ming
    Zhao, Hui
    Shah, Mohsin
    Diab, Adi
    Shannon, Vickie
    Patel, Anisha
    Amaria, Rodabe Navroze
    Giordano, Sharon Hermes
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Immune-related hypophysitis in three patients with metastatic melanoma undergoing Ipilimumab treatment
    Tsioga, M.
    Voigtlaender, R.
    Suttorp, W.
    Zimmer, L.
    Schlamann, M.
    Sure, U.
    Lahner, H.
    Moeller, L. C.
    Fuehrer, D.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2013, 121 (03)
  • [45] PERICARDIAL EFFUSION WITH TAMPONADE PHYSIOLOGY AS AN IMMUNE-RELATED ADVERSE EVENT SECONDARY TO NIVOLUMAB
    Malhotra, Nikhil
    Daher, Ghassan
    Hassanieh, Ihab
    Schoen, Martinq W.
    Helmy, Tarek
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 2613 - 2613
  • [46] Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
    Nakamura, Hajime
    Shionoya, Aika
    Arihara, Yohei
    Hayasaka, Naotaka
    Kubo, Tomohiro
    Usami, Makoto
    Sugita, Shintaro
    Uhara, Hisashi
    Takada, Kohichi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event
    C. Mangas
    S. Leoni-Parvex
    V. Spataro
    Cancer Immunology, Immunotherapy, 2020, 69 : 2409 - 2410
  • [48] TEMPORAL TRENDS IN ADVERSE EVENT COSTS WITH NIVOLUMAB plus RELATLIMAB COMBINATION THERAPY OR NIVOLUMAB MONOTHERAPY FOR PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
    Garcia-Horton, V
    Zhou, Z. Y.
    Moshyk, A.
    Rosenblatt, L. C.
    Patel, D.
    Xin, Y.
    Wang, Q.
    Christensen, D.
    Palaia, J.
    VALUE IN HEALTH, 2023, 26 (06) : S108 - S108
  • [49] Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event
    Mangas, C.
    Leoni-Parvex, S.
    Spataro, V.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2409 - 2410
  • [50] Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab
    Nakamagoe, Kiyotaka
    Yamada, Takeshi
    Okune, Sho
    Moriwaki, Toshikazu
    Tamaoka, Akira
    ACTA NEUROLOGICA BELGICA, 2021, 121 (05) : 1381 - 1382
12345